Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 15:6:1002324.
doi: 10.37349/etat.2025.1002324. eCollection 2025.

Osteosarcoma: current insights and advances

Affiliations
Review

Osteosarcoma: current insights and advances

Guraustin S Brar et al. Explor Target Antitumor Ther. .

Abstract

Osteosarcoma is the most prevalent primary malignant bone tumor affecting adolescents and young adults. Despite advancements in cancer therapies, its prognosis remains poor due to its aggressive nature and early propensity for metastasis-often present at the time of diagnosis. The etiology of osteosarcoma is multifactorial, involving genetic predispositions, environmental exposures, and familial syndromes. While treatment strategies are largely dictated by tumor stage, neoadjuvant chemotherapy followed by surgical resection remains the cornerstone of management. This review provides a comprehensive overview of osteosarcoma, including its historical context, subclassifications, clinical presentation, diagnostic approaches, and evolving treatment modalities. Recent therapeutic innovations-such as gene therapy, immunotherapy, radiation advances, and tyrosine kinase inhibitors-are discussed in detail, highlighting their mechanisms and clinical potential. By synthesizing current literature and identifying ongoing challenges, this review aims to inform clinicians and researchers of recent progress while highlighting critical gaps to guide future research and improve patient outcomes in osteosarcoma care.

Keywords: Osteosarcoma; gene therapy; immunotherapy; radiation; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

Yujiang Fang, who is the Editorial Board Member of Exploration of Targeted Anti-tumor Therapy, had no involvement in the decision-making or the review process of this manuscript. Other authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
A schematic representation of the CRISPR/Cas9, base editing, and prime editing mechanisms, which compares the differences in components, progress, and outcomes for the three techniques [32, 34]

Similar articles

References

    1. Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, et al. Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest. 2020;38:259–69. doi: 10.1080/07357907.2020.1768401. - DOI - PubMed
    1. Chen G, Li M, Xiao X, Ji C, Huang M, Wang Z, et al. A classification system of joint-salvage tumor resection in osteosarcoma of the knee: A retrospective cohort study. Knee. 2023;41:221–31. doi: 10.1016/j.knee.2023.01.011. - DOI - PubMed
    1. Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 2017;405:90–9. doi: 10.1016/j.canlet.2017.07.024. - DOI - PubMed
    1. Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016;2016:3631764. doi: 10.1155/2016/3631764. - DOI - PMC - PubMed
    1. Deepak KV, Bharanidharan R. A survey on deep learning and machine learning techniques over histopathology image based Osteosarcoma Detection. Multimed Tools Appl. 2025;84:15763–86. doi: 10.1007/s11042-024-19554-5. - DOI

LinkOut - more resources